The fight against global diseases like HIV and HBV just got a boost, as Novira Therapeutics, an antiviral drug discovery company, announced it has raised $9.0M in Series A funding. The capital will advance its work on novel, first-in-class therapeutics aimed at these critical health challenges.
Founded in 2009 and led by Ali H. Munawar and a team of seasoned pharma executives, Novira Therapeutics employs an efficient and innovative biomedical research model. The company has already identified and is optimizing a promising pipeline of drugs designed to disrupt virus capsid assembly, offering a new approach to treatment.












.png&w=3840&q=75)




